Mini-Reviews in Medicinal Chemistry

Journal Impact Factor: 3.3
Scopus Cite Score: 8.5

Indexed in: Scopus, SCI Expanded, MEDLINE/PubMed

View All
Aims and Scope:
The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines.
Mini-Reviews in Medicinal Chemistry covers all areas of medicinal chemistry, including quantitative structure-function relationships, synthetic chemistry, bioorganic chemistry, drug absorption, drug distribution, drug metabolism, new and emerging drug targets, pharmacogenomics, drug safety profile and drug-induced liver injury (DILI), drug discovery toxicology, high-throughput screening, combinatorial chemistry, structural characterization and organic syntheses of naturally occurring compounds, "nanosystem and nanocarriers", as well as chemical and analytical techniques used in rational drug design.
Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to remain informed and up-to-date with the latest and most important developments.
Read more...
Start Submission Button Icon

Editor-in-Chief:

  • Davide Barreca Department of Chemical, Biological
    Pharmaceutical and Environmental Sciences
    University of Messina
    Messina
    Italy

ISSN: 1389-5575 (Print)

eISSN: 1875-5607 (Online)

Special Issues With Active Call for Papers

Submission closes on: Feb 18, 2027
Innovative Approaches, Methods, and Tools for Medicinal Chemistry in an AI Era

The advent of robust and faster computational tools and algorithms have revolutionized the work of chemical and pharmaceutical laboratories. Artificial intelligence and machine learning algorithms have demonstrated potential roles in synthetic planning of small molecules. In silico synthetic planning is a novel approach recently adopted by few companies that are a part of Machine Learning for Pharmaceutical Discovery and Synthesis (MLPDS) Consortium. Thus, integration of AI and Machine learning (ML) such as the Computer Aided... see more

Impact Factor: 3.3
Guest Editor(s): Dr. Venkatraman Subramanian Gowri
Co-Guest Editor(s): Dr. Heba M M Afify,Dr. Varatharajan Sabareesh
Start Submission
Submission closes on: Feb 05, 2027
Metal–Organic Frameworks: From Atomic Design to Biomedical Frontiers

The proposed thematic issue focuses on Metal–Organic Frameworks (MOFs) as transformative materials engineered through the principles of reticular chemistry. Following their recognition by the 2025 Nobel Prize in Chemistry, MOFs have gained renewed significance for their tunable structures, scalability, and translational potential across disciplines. This issue aims to bridge the atomic-level design principles with scalable green synthesis strategies, computational modeling, and emerging biomedical applications. Emphasis will be placed on mechanochemical and solvent-free synthesis, machine learning-driven... see more

Impact Factor: 3.3
Guest Editor(s): Dr. Neha Vithal Bhilare
Co-Guest Editor(s): Dr. Pratibha Auti,Dr. Shubham Vasudev Khot
Start Submission
Submission closes on: Jan 29, 2027
Natural Products-Based Pesticidal and Medicinal Agents

Natural bioactive products (NBPs) with unique chemical structures and a variety of biological activities have always received much attention. Therefore, in this issue, entitled “Natural Products-Based Pesticidal and Medicinal Agents”, we will present recent advances on four sub-topics in the fields of medicine and agriculture, namely, isolation and structural elucidation of natural bioactive products (NBPs), structural modification of NBPs, synthesis of NBPs derivatives, and discovery of the mechanism of NBPs. Original research and review articles... see more

Impact Factor: 3.3
Guest Editor(s): Dr. Hui Xu
Co-Guest Editor(s): Dr. Ning Huang,Dr. Kang Lei,Dr. Danling Huang
Start Submission
Submission closes on: Nov 16, 2026
Next-Generation Protein Degradation: From Chemically Engineered PROTACs to AI-Designed BIO-degraders

Protein-targeted degradation has evolved far beyond traditional small-molecule PROTACs. This issue will capture the entire innovation spectrum: covalent PROTACs, molecular-glue degraders, antibody-based (AbTACs), peptide-PROTACs, lipid-anchored LYTACs, ribonucleoprotein RIBOTACs, photo-activated PhotoTACs, CRISPR-enabled epigenetic erasers, and AI-generated mini-protein degraders. Reviews will highlight how these modalities expand the druggable proteome, improve cell-type selectivity, and integrate with gene-therapy vectors, nanoparticles, or oncolytic viruses. Both computational advances (deep-learning de-novo design, physics-aware virtual screening, multi-objective ADMET prediction) and wet-lab breakthroughs (high-throughput... see more

Impact Factor: 3.3
Guest Editor(s): Dr. Xia Qi-Dong
Co-Guest Editor(s): Dr. Si-Han Zhang
Start Submission
Submission closes on: Oct 05, 2026
Research Developments in Enzyme-Activated Drugs, Photodynamic Therapeutic, Anticancer, and Bioimaging Agents

Enzymes are critical biological catalysts that govern a wide variety of physiological functions and cellular processes. The dysregulation of different enzymatic processes is related to different diseases, cell proliferation and cancer progression, and metastasis. Therefore, targeting an enzyme in a particular disease or cancer, and designing a PDT, anticancer, or bioimaging agent that could be activated by that enzyme, is one of the most important research areas. Enzyme-activated PDT is a mandatory approach in cancer... see more

Impact Factor: 3.3
Guest Editor(s): Dr. Faiz Ur Rahman
Start Submission
Submission closes on: Oct 04, 2026
The Role of Natural Lead Compounds in Modern Drug Discovery

Pharmaceutical innovation has historically relied on natural products as a foundation, providing scaffolds for drug discovery that are both physiologically active and physically diverse. Advances in synthetic biology, analytical chemistry, and computational modelling have rekindled the hunt for natural lead compounds from marine, microbial, and plant sources in the modern period. With its focus on identification, structural optimization, mechanism of action research, and integration with high-throughput and in silico screening methods, this thematic issue emphasizes... see more

Impact Factor: 3.3
Guest Editor(s): Dr. Anurag Khatkar
Co-Guest Editor(s): Dr. Priyanka Rathee,Prof. (Dr.) Sarita Khatkar,Prof. (Dr.) Esra Küpeli Akkol
Start Submission
Submission closes on: Sep 27, 2026
Advances and Novel Methodologies for the Development of Small-Molecule Drugs

Over the past decade, small-molecule drugs have remained the dominant force among approved therapeutics. Recent advances in artificial intelligence and structural biology now enable researchers to discover novel targets for small molecule inhibitors with greater precision and to pursue rational drug design, markedly accelerating the development of new small molecule drugs. Looking ahead, small-molecule drugs are poised to be deployed across an even broader spectrum of diseases. This Special Issue aims to spotlight recent advancements... see more

Impact Factor: 3.3
Guest Editor(s): Dr. Qiangsheng Zhang
Co-Guest Editor(s): Dr. Yong Chen,Dr. Zhihao Liu
Start Submission
Submission closes on: Sep 18, 2026
Artificial Intelligence and Generative Models in Medicinal Chemistry: From Molecular Design to Clinical Translation

This Thematic Issue will focus on the integration of artificial intelligence (AI) and generative models into medicinal chemistry, highlighting how these tools are reshaping drug discovery and development. The issue will provide readers with an overview of state-of-the-art algorithms, successful case studies, and translational opportunities, while also addressing current challenges such as model interpretability, data bias, and regulatory acceptance. The ultimate goal is to offer a comprehensive perspective on how AI-driven approaches can accelerate the... see more

Impact Factor: 3.3
Guest Editor(s): Dr. Anna Artese
Co-Guest Editor(s): Dr. Roberta Rocca
Start Submission
Submission closes on: Sep 07, 2026
Cutting-Edge Medicinal Chemistry for Tropical Neglected Diseases: Recent Breakthroughs, Emerging Targets and Translational Strategies

Neglected Tropical Diseases (NTDs) such as leishmaniasis, Chagas disease, schistosomiasis, filariasis, and dengue fever continue to impose a heavy health and economic burden on populations in developing regions. Despite affecting over a billion people globally, these diseases remain underfunded and understudied due to their limited commercial appeal. Recent advances in medicinal chemistry, coupled with computational drug design, nanotechnology, repurposing strategies, and biomolecular target elucidation, have opened promising avenues for developing safer, more effective, and affordable... see more

Impact Factor: 3.3
Guest Editor(s): Dr. Rajesh K. Singh
Co-Guest Editor(s): Dr. Rohit Bhatia
Start Submission
Submission closes on: Sep 06, 2026
Novel Paradigms in Multiple Disease Targets

The "one drug-one target" concept of drug discovery has been gradually replaced by multi-target therapeutic integration strategies. Various kinds of neurodegenerative diseases in combination with cardiovascular disorders, metabolic syndromes, cancer, and infectious diseases, are chronic and complex and share common pathways and signaling cascades. Their simultaneous targeting can greatly enhance the effect of their treatment, but also decrease drug resistance and disease progression. In the thematic issue, we are working on the same, focusing on... see more

Impact Factor: 3.3
Guest Editor(s): Dr. Pooja A. Chawla
Start Submission